These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28433474)

  • 1. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
    Zingariello CD; Elder ME; Kang PB
    Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
    Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
    JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
    Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
    Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
    [No Abstract]   [Full Text] [Related]  

  • 11. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
    Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
    Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.
    Wang J; Wu X; Deng H; Liu Y; Liu H; Fan X; Liu K; Wu J; Zhang HL
    Neurosciences (Riyadh); 2016 Jan; 21(1):77-8. PubMed ID: 26818174
    [No Abstract]   [Full Text] [Related]  

  • 15. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
    Stieglbauer K; Pichler R; Topakian R
    J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
    J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
    J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.